Novartis faces a mounting problem in Japan, its second-largest market, where researchers have retracted studies that touted the benefits of the company’s most popular medicine according to the Wall Street Journal.
Pharmas collaborating increasingly with universities. Novartis and the University of Pennsylvania announced a research and licensing agreement that aims to bring to market a new approach to fighting cancer that has shown promising results in early trials.
Roche vs. Novartis! Roche Holding AG will pay as much as $490 million for experimental drugs from PTC Therapeutics Inc. to treat a genetic muscle-weakening disease, in a deal that sets up a race with rival Novartis AG.
IBM and Novartis announced the NCD Challenge, a competition among a number of the world’s leading universities designed to tap the inventiveness of students to find new ways to address the rise of non-communicable diseases in both developing and developed countries.
Pfizer’s campaign to promote Lyrica is part of a stepped-up arms race among Western drug makers for a bigger presence in Japan, the world’s second-largest pharmaceuticals market after the U.S., with about $100 billion in yearly sales.